Published in final edited form as:

Bioorg Med Chem Lett. 2009 June 1; 19(11): 2928–2930. doi:10.1016/j.bmcl.2009.04.069.

Synthesis and Structure-Activity Relationships of Bengazole A Analogs

Roger J. Mulder^{c,†}, Cynthia M. Shafer^{c,§}, Doralyn S. Dalisay^a, and Tadeusz F. Molinski^{a,b,c,*}

^a Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093

^b Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093

^c Department of Chemistry, University of California Davis, 1 Shields Avenue, Davis, CA 95616

Abstract

Analogues of the potent antifungal agent, bengazole A, were prepared and evaluated against *Candida* spp. in both microbroth dilution and disk diffusion assays.

Keywords

antifungal; oxazole;azole; marine natural product

Bengazoles A (**1**) and B (**2**) are homologous *bis*-oxazole natural products first reported by Crews and coworkers from the sponge *Jaspis* sp. with anthelmintic activity against the nematode *Nippostrongylus braziliensis*.¹

In 1990 we re-isolated **1** and **2**, together with five additional homologs, bengazoles C-G (**3a-e**), from *Jaspis* sp. collected on the Great Barrier Reef,² during a bioassay-guided screening of marine organisms for antifungal activity and found both compounds exhibited exceptionally potent *in vitro* activity against *Candida albicans* (e.g., MIC 1 µg/mL, *C. albicans* ATCC 14503),³ a pathogenic fungus that is responsible for systemic infections in immunocompromised individuals, including AIDS patients. The absolute stereostructure of **1** was determined using a combination of chemical degradation, synthesis of model compounds and comparisons of the CD spectra of perbenzoyl derivatives of both models and the natural product.² Only total syntheses of bengazoles have been reported; bengazole A (**1**) by our group in 1999⁴ and, more recently, **1** and **2** by Ley,⁵ and ‘bengazole Z’ (**4**) by Shioiri.⁶ The *bis*-oxazole, digonazole from *J. digonoxea* and its homologs,^{1b} lack the C10 acyloxy group of **1**–**3**,⁷ and have not been made or evaluated.

The mechanism of action of **1** is unknown and only limited of structure-activity relationships (SAR) are available.⁷ The clinically important ‘azole’ antifungal drugs (e.g., fluconazole (**5**), miconazole and voriconazole) inhibit 14- α -demethylase in yeast by tight binding of one of the

*Corresponding author: Tel: +1 858 534-7115; Fax: +1 858 822-0386; email: E-mail: tmolinski@ucsd.edu.

†Present address: CSIRO Molecular and Health Technologies, Clayton, Vic, 3169, Australia

§Present address: Novartis Biosciences, Emeryville, CA, USA.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1,2,4-triazole rings to the Fe-heme active site.⁸ A cursory comparison of the structures of **1** and **4** suggested one of the oxazole rings in **1** might play a similar role, although this is not certain and other structural elements also appear to be important.

Bengazole **1** exhibits ergosterol-dependent in vitro activity against *C. albicans* similar to amphotericin B (AmB). When grown on agar plates containing Sabouraud media and defined concentrations of ergosterol or cholesterol, *C. albicans* showed diminished susceptibility that was dose-dependent upon **1**, but inversely dependent upon the sterol concentration.⁹ Conversely, the activity of miconazole, exhibited no ergosterol-dependence.^{9b} Interestingly, incorporation of cholesterol or synthetic *ent*-cholesterol^{9c} in the media elicited dose-dependent, differential suppression of susceptibility of *C. albicans* towards AmB, but no enantiospecific differences were observed with (–)- and (+)-cholesterol and **2**.^{9a}

Here, we report the synthesis of new bengazole A analogs and an advanced SAR study of the new and known compounds that reveal the importance of structural features in **1** for anti-*Candida* activity; a long-hydrophobic side-chain, the polyol side chain, and at least one oxazole in the heterocyclic core.

The fatty acyl side chain of **1** is important for antifungal activity. We observed that **1** was prone to spontaneous solvolysis in the presence of protic solvents, or more rapidly, by ammoniolysis (NH₃, MeOH).² The des-acyl product, ‘bengazole Z’ (**4**),¹⁰ showed no anti-*Candida* activity in disk diffusion assays.

In order to examine the role of the heterocyclic core of **1**, analogs were prepared with replacement of the polyol side-chain with a simple 1-hydroxy-1-butyl group (the parent, 1,3-oxazole (**6**) is too volatile, b.p. 69–70°C, for bioassay).

Compounds **7a–c** were prepared by a variant of the ‘oxazole grafting’ approach employed for the synthesis of **1** (Scheme 1).^{4,11} Aldehyde **8** (prepared by DIBAL reduction of ethyl oxazole-4-carboxylate) was treated with *n*-PrMgBr and the product **9** was protected as the silyl ether **10** (TBSCl, imidazole, THF). Deprotonation of **10** using the Vedejs’ protocol¹² (*i.* –78 °C, THF/hexanes, *ii.* BH₃•THF), followed by separate additions of three aldehydes (oxazole-5-carboxaldehyde, **11a**,¹³ furfural, **11b** and benzaldehyde, **11c**), gave 2,4-substituted oxazole adducts **12a–c**.¹⁴

Diastereomeric mixtures of the secondary carbinols **12a–c** were acylated in good yield (myristoyl chloride, Et₃N, DMAP) to give the long-chain esters **13a–c** that were deprotected (TBAF, THF) to afford bengazole A analogs **7a–c**. This small library, **7a–c**, **12a–c** and **13a–c**, was tested in paper disk diffusion assays against *Candida albicans* (96–489, a patient clinical isolate, and ATCC 14503), *C. glabrata* and *C. krusei*. To our surprise, none were active at doses of up to 300 µg/disk. In order to determine the properties of mono-oxazole analogs of **1**, selected 5- and 2,5-substituted oxazoles (Scheme 2) were tested in disk diffusion assays against five species of *Candida* including fluconazole-resistant *C. glabrata*, *C. krusei* and *C. albicans* (Table 1).

The preparation of alcohols **14a–g**, **15a,d,g**, ketones **14h** and **15h**, and 2-methylthio-5-butyl-oxazole (**16**), starting with 2-methylthiooxazole (**17**),¹⁶ have been reported previously¹⁵ and summarized in Scheme 2. Selected alcohols **14** and **15** were *O*-acylated (EDCI, DMAP, *n*-C₁₃H₂₇COOH) group to give the new myristate esters **18** and **19**. When assayed against fungi (Table 1), all compounds were found to be less potent than **1** or AmB. The most active compounds were **14c** (9–17 mm zones of inhibition) and ketones **14h** (8–12 mm) and **15h** (9–12 mm). 2-Methylthio-5-oxazolyl analog **14a** appeared to be slightly less active than its 5-monosubstituted counterpart **15a**. Surprisingly, myristate esters **18a,c,g** and **19a,g** lost activity compared to their active parent alcohols, suggesting the activities of the compounds were

limited by solubility. This contrasts with **1** where the fatty acyl chain is required for activity. Intermediates **20a** and **20b**, employed in the synthesis of **1**,⁴ (Table 1) showed modest activity (9–10 mm) although diastereomer **20a**, matching the configuration of **1**, was slightly more active with a susceptibility profile similar to that of **1**.

The most active compounds retained antifungal activity when tested in microbroth dilution assays (Table 2, e.g. **14c**, MIC = 4 µg/mL against *C. albicans* and *C. krusei*), but again, myristate esters **18c,d** and **19d** were inactive.

Clearly, the antifungal activity of **1** is not accounted for by simple analogs with one or two oxazole rings alone. At the very least, activity was correlated with the presence of a 5-monosubstituted oxazole (Scheme 2). 2,4-Disubstituted oxazolyl carbinol analogs, including their long-chain esters, were inactive. Interestingly, the closest heterocyclic analog, **7a**, to bengazole A (**1**), was inactive suggesting abrogation of biological activity upon replacement of the hydrophilic polyol side chain of **1** with a truncated *n*-propyl carbinol. The fatty acyloxy chain at C-10 potentiates activity *only* when the native polyol chain is present (e.g. **1**) since highly lipophilic **18a,c,g** and **19a,g** are inactive.

Although lipophilicity plays a role in activity of bengazole analogs, not all the effects can be explained by simple log*P* considerations, and subtle effects appear to be conferred by both the hydrophilic and fatty acyl chains.

In summary, several analogs of bengazole A (**1**) were prepared, containing one or two 1,3-oxazole rings, and modified side chains. Good activity was observed in some compounds but none were more potent than **1**.

Partial recovery of susceptibility of *Candida* strains was observed in some 5-monosubstituted oxazole analogs. These findings will guide further development of antifungal analogs of **1**, particularly modifications of the lipophilic acyl and hydrophilic polyol side-chains.¹⁸

Acknowledgments

We thank the Great Barrier Reef Authority for the permit to collect of *Jaspis* sp. This work was funded by the NIH (AI 039987).

References and Notes

- (a) Adamczeski M, Quiñoà E, Crews P. J Am Chem Soc 1988;110:1598. (b) Rodríguez J, Nieto RM, Crews P. J Nat Prod 1993;56:2034. [PubMed: 8133293]
- Searle PA, Richter RK, Molinski TF. J Org Chem 1996;61:4073. [PubMed: 11667285]
- Bengazole A (**1**) shows no antibacterial activity against gram-positive (*Escherichia coli*, *Staphylococcus aureus*) or gram-negative strains (*Pseudomonas aeruginosa*).
- (a) Mulder RJ, Shafer CM, Molinski TF. J Org Chem 1999;64:4995. [PubMed: 11674590] (b) Shafer CM, Molinski TF. Tetrahedron Lett 1998;39:2903.
- (a) Bull JA, Balskus EP, Horan RAJ, Langner M, Ley SV. Angew Chem Intl Ed 2006;45:6714. (b) Bull JA, Balskus EP, Horan RAJ, Langner M, Ley SV. Chem Eur J 2007;13:5515.
- Chittari P, Hamada Y, Shioiri T. Heterocycles 2003;59:465.
- Rudi A, Kashman Y, Benayahu Y, Schleyer M. J Nat Prod 1994;57:829. [PubMed: 7931369]
- Trinci, APJ.; Ryley, JF., editors. Mode of Action of Antifungal Agents. Cambridge; 1984.
- (a) Richter RK, Mickus DE, Rychnovsky SD, Molinski TF. Bioorg Med Chem Lett 2004;14:115. [PubMed: 14684310] (b) Molinski TF. J Nat Prod 1993;56:1. [PubMed: 8450313] (c) Mickus DE, Levitt DG, Rychnovsky SD. J Am Chem Soc 1992;114:359.
- 'Bengazole Z', a name coined by P. Crews for des-acyl **1**, was found in methanol extracts of *Jaspis* sp. along with **1** and **2**. See Ref. 1b.

11. Hodges JC, Patt WC, Connolly CJ. *J Org Chem* 1991;56:449.
12. Vedejs E, Monahan SD. *J Org Chem* 1996;61:5192.
13. (a) Kende AS, Kawamura K, DeVita RJ. *J Am Chem Soc* 1990;112:4070. (b) Schöllkopf U, Schröder R. *Angew Chem, Int Ed* 1971;10:333.
14. Generally, the diastereomers (*dr* ~1:1, ¹H NMR) were inseparable by TLC; no attempt was made to purify the isomers. All compounds gave satisfactory spectroscopic data.
15. (a) Shafer CM, Molinski TF. *J Org Chem* 1998;63:551. [PubMed: 11672044] Shafer, CM. PhD Thesis. University of California; Davis: 1998.
16. Lacasse G, Muchowski JM. *Can J Chem* 1972;50:3082.
17. Wong MYH, Gray GR. *J Am Chem Soc* 1978;100:3548.
18. A recent report describes synthesis of 'bengazole analogs' and their antimicrobial activity. The compounds are actually based on 2,5-disubstituted furans; none of the analogs contain an oxazole ring. Kraus J, Kalkbrenner S, Schuster A, Obainoke A, Bracher F. *Turk J Chem* 2008;32:125.

Figure 1.
Bengazoles A–G (**1–3**), -Z (**4**), fluconazole (**5**) and oxazole (**6**)

Scheme 1.
Synthesis of truncated 2,4-disubstituted oxazole analogs of **1**.

Scheme 2.

2-Methylthio-, 5- and 2,5-disubstituted oxazoles. See Ref. 15 for **14a-g**, and **15a,d,g**, Ref. 4 for **18a:18b**, and Ref. 15b. for **16**.

Table 1
Anti-*Candida* activity of analogs of **1**: disk diffusion assays.

Cmpd.	Zones of inhibition. mm @ 300 µg/disk ^a				
	<i>C. albicans</i> ^c	<i>C. glabrata</i>	<i>C. krusei</i>	<i>C. albicans</i> ^{d,e}	<i>C. albicans</i> ^e
1 ^b	50	15	35	15	50
14a	10	0	9	9	9
14b	8	7.5	0	0	7.5
14c	13	10	9	12	17
14d	7.5	0	6.5	8	9
14e	8	7.5	7.5	0	8
14f	8	7	0	0	7
14g	0	0	0	0	0
14h	8	7	11	10	12
15a	10	0	9	12	12
15d	10	0	7.5	8	8
15g	0	0	0	0	0
15h	9	10	8	12	—
16	8	0	7	0	—
18a,c,g	0	0	0	0	0
19a,g	0	0	0	0	0
20a	10	0	9	0	0
20b	8	0	0	0	0
AmB ^f	22	19	15	12	23

^a Sabouraud agar. “—”, not tested.

^b 10 µg/disk.

^c ATCC 14503.

^d 96-489, patient isolate, Ref. 9b.

^e UCDFR1, fluconazole-resistant (MIC >32 µg/mL), see Ref. 9b.

^f AmB, amphotericin B (5 µg/disk).

Table 2Anti-*Candida* activity of analogs of **1**: minimum inhibitory concentrations (MIC's).^a

Cmpd.	<i>C. albicans</i> ^c	<i>C. krusei</i> ^{b,d}	<i>C. albicans</i> ^e
1	1	—	1
14c	4	4	8
14d	8	16	8
15d	>64	>64	32
18c	>64	>64	>64
18d	>64	>64	>64
19d	>64	>64	>64
AmB	0.50	0.25	0.50

^a RPMI media, 37 °C, 24 h incubation.^b 48 h incubation.^{c-e} See caption in Table 1 for strain identification.